Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel liposome encapsulated - INSYS Therapeutics

Drug Profile

Paclitaxel liposome encapsulated - INSYS Therapeutics

Alternative Names: LEP; LEP-ETU; Liposome encapsulated paclitaxel; Liposome entrapped paclitaxel; NeoLipid™ paclitaxel; ONC 0355; Paclitaxel liposomal - INSYS Therapeutics; PNU 914; PNU 93914

Latest Information Update: 15 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Georgetown University
  • Developer INSYS Therapeutics, Inc
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Cervical cancer; Cholangiocarcinoma; Gastric cancer; Ovarian cancer

Most Recent Events

  • 28 May 2018 No recent reports of development identified for preclinical development in Gastric-cancer in USA (IV)
  • 28 May 2018 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (IV)
  • 18 Oct 2016 Phase-II clinical trials in Cervical cancer in USA (IV) (INSYS Therapeutics pipeline October 2016)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top